If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can…
In Conversation
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main…
What is the importance of the UK operations for Takeda worldwide? Our UK operation was established in 1997 and is relatively younger than other affiliates in…
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few…
You used to be the Managing Director of Ranbaxy in China. Having moved to a directorship in the UK, what professional challenges do you see in…
Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just…
Before joining Bristol-Myers Squibb (BMS), you have spent roughly twenty years with GSK. Can you describe the trajectory of your career and explain what attracted you…
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of…
Astellas’s European headquarters is based in the UK. What does the UK market represent for the company? Speaking from a global perspective, 60% of Astellas’ business…
This year’s Q1 results for Novo Nordisk were extremely positive with a 23% increase in profit. While this growth was mostly driven by the US and…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market…
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself…
